Keyphrases
Ado-trastuzumab
50%
Adult Subjects
10%
Adverse Event Data
10%
Adverse Events
20%
Angina
25%
Breast Cancer
10%
Cancer Treatment
10%
Chest Pain
25%
Clinical Efficacy
10%
Clinical Outcomes
10%
Clinical Testing
10%
Clinical Trials
50%
Data Extraction
10%
Diabetic Retinopathy Treatment
12%
Drug Development
50%
Drug Efficacy
10%
Drug Risk
10%
Etiology
25%
FDA-approved Drugs
20%
Future Doctors
10%
Heart Attack
25%
Inclusion Criteria
10%
Intubated
50%
Literature Search
10%
Median Overall Survival
10%
Median Progression-free Survival
10%
Monotherapy
10%
Myocardial Infarction
50%
Objective Response Rate
20%
Off-label Indications
10%
Overall Survival
10%
Patient Benefit
50%
Patient Outcomes
50%
Patient Risk
50%
Pneumoperitoneum
50%
Progression-free Survival
10%
Quality of Life
10%
Risk Outcomes
50%
Risk-benefit
50%
Solid Tumors
10%
ST-elevation Myocardial Infarction (STEMI)
50%
Survival Response
10%
T-DM1
50%
Trastuzumab Emtansine
10%
Treatment Burden
10%
Trial Characteristics
10%
Trial Outcomes
10%
Trial Participants
10%
Typical Symptoms
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Breast Cancer
8%
Clinical Trial
100%
Cross-Sectional Study
10%
Diabetic Retinopathy
50%
Drug Development
50%
Malignant Neoplasm
16%
Monotherapy
8%
Overall Survival
16%
Progression Free Survival
16%
Solid Malignant Neoplasm
8%
Trastuzumab
50%
Trastuzumab Emtansine
8%
Nursing and Health Professions
Cross-Sectional Study
10%
Data Extraction
10%
Diabetic Retinopathy
50%
Embase
10%
Heart Infarction
50%
Medline
10%
Pneumoperitoneum
50%
ST Segment Elevation Myocardial Infarction
50%
Sulfanilamide
16%
Thorax Pain
16%
Underserved Population
20%
